secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001558370-25-011468
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix Q2 2025: Revenue $15.4M (+16% YoY), net income $164K; CFO transition, PRX-115 trial on track
--------------------------------------------------------------------------------

- Revenue from goods $15.4M (+16% YoY); net income $164K vs $2.2M loss, EPS $0.00.
- Elfabrio sales to Chiesi up $8M; EMA reviews label extension for every-4-weeks dosing.
- CFO Eyal Rubin steps down Aug 24, replaced by Gilad Mamlok; transition through October.
- PRX-115 Phase 2 for uncontrolled gout planned H2 2025; first patient enrollment Q4 2025.
- Cash $33.4M; R&D doubled to $6M on PRX-115 prep; added to Russell 2000/3000 indexes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837025011468/0001558370-25-011468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837025011468/plx-20250814x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-011468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer